Follow the people · Insider
Ingrid Delaet
Ingrid Delaet files insider transactions with the SEC as a chief regulatory officer of Neurocrine Biosciences (NBIX). We hold 5 disclosed purchases and sales filed since 15 February 2023, 4 of them in the last 90 days.
- Files forNBIX
- Disclosed buys and sells5 in all, 4 in the last 90 days
- Last disclosure13 July 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 13 February 2023 — 10 July 2026Chief Regulatory Officer · Neurocrine Biosciences (NBIX)129 Form 4 lines · source: SEC Form 4
Everything they disclosed
120 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 4,367 shares of Neurocrine BiosciencesSEC Form 413 July 2026Common Stock · traded 10 July 2026 · filed 13 July 2026
- ▼ sold on the open market 4,367 shares of Neurocrine BiosciencesSEC Form 413 July 2026Common Stock · traded 10 July 2026 · filed 13 July 2026
- exercised options over 4,367 shares of Neurocrine Biosciences (a derivative holding)SEC Form 413 July 2026Non-Qualified Stock Option · traded 10 July 2026 · filed 13 July 2026
- exercised options over 3,401 shares of Neurocrine BiosciencesSEC Form 49 July 2026Common Stock · traded 7 July 2026 · filed 9 July 2026
- ▼ sold on the open market 3,401 shares of Neurocrine BiosciencesSEC Form 49 July 2026Common Stock · traded 7 July 2026 · filed 9 July 2026
- exercised options over 2,737 shares of Neurocrine BiosciencesSEC Form 49 July 2026Common Stock · traded 8 July 2026 · filed 9 July 2026
- ▼ sold on the open market 2,737 shares of Neurocrine BiosciencesSEC Form 49 July 2026Common Stock · traded 8 July 2026 · filed 9 July 2026
- exercised options over 8,433 shares of Neurocrine BiosciencesSEC Form 49 July 2026Common Stock · traded 9 July 2026 · filed 9 July 2026
- ▼ sold on the open market 8,433 shares of Neurocrine BiosciencesSEC Form 49 July 2026Common Stock · traded 9 July 2026 · filed 9 July 2026
- exercised options over 3,401 shares of Neurocrine Biosciences (a derivative holding)SEC Form 49 July 2026Non-Qualified Stock Option · traded 7 July 2026 · filed 9 July 2026
- exercised options over 2,737 shares of Neurocrine Biosciences (a derivative holding)SEC Form 49 July 2026Non-Qualified Stock Option · traded 8 July 2026 · filed 9 July 2026
- exercised options over 8,433 shares of Neurocrine Biosciences (a derivative holding)SEC Form 49 July 2026Non-Qualified Stock Option · traded 9 July 2026 · filed 9 July 2026
- exercised options over 2,261 shares of Neurocrine BiosciencesSEC Form 42 June 2026Common Stock · traded 29 May 2026 · filed 2 June 2026
- ▼ sold on the open market 2,261 shares of Neurocrine BiosciencesSEC Form 42 June 2026Common Stock · traded 29 May 2026 · filed 2 June 2026
- exercised options over 2,261 shares of Neurocrine Biosciences (a derivative holding)SEC Form 42 June 2026Non-Qualified Stock Option · traded 29 May 2026 · filed 2 June 2026
- exercised options over 1,600 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 12 February 2026 · filed 17 February 2026
- exercised options over 1,401 shares of Neurocrine Biosciences (a derivative holding)SEC Form 417 February 2026Restricted Stock Unit · traded 13 February 2026 · filed 17 February 2026
- exercised options over 1,359 shares of Neurocrine Biosciences (a derivative holding)SEC Form 417 February 2026Restricted Stock Unit · traded 13 February 2026 · filed 17 February 2026
- was granted 31,234 shares of Neurocrine Biosciences (a derivative holding)SEC Form 417 February 2026Stock Option · traded 13 February 2026 · filed 17 February 2026
- was granted 5,479 shares of Neurocrine Biosciences (a derivative holding)SEC Form 417 February 2026Restricted Stock Unit · traded 13 February 2026 · filed 17 February 2026
- had shares withheld for tax on 881 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 12 February 2026 · filed 17 February 2026
- exercised options over 1,401 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- exercised options over 1,600 shares of Neurocrine Biosciences (a derivative holding)SEC Form 417 February 2026Restricted Stock Unit · traded 12 February 2026 · filed 17 February 2026
- exercised options over 1,401 shares of Neurocrine Biosciences (a derivative holding)SEC Form 417 February 2026Restricted Stock Unit · traded 13 February 2026 · filed 17 February 2026
- exercised options over 1,359 shares of Neurocrine Biosciences (a derivative holding)SEC Form 417 February 2026Restricted Stock Unit · traded 13 February 2026 · filed 17 February 2026
- was granted 31,234 shares of Neurocrine Biosciences (a derivative holding)SEC Form 417 February 2026Stock Option · traded 13 February 2026 · filed 17 February 2026
- was granted 5,479 shares of Neurocrine Biosciences (a derivative holding)SEC Form 417 February 2026Restricted Stock Unit · traded 13 February 2026 · filed 17 February 2026
- had shares withheld for tax on 756 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- exercised options over 1,359 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- had shares withheld for tax on 734 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- was granted 19,935 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- had shares withheld for tax on 10,755 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- exercised options over 1,600 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 12 February 2026 · filed 17 February 2026
- had shares withheld for tax on 881 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 12 February 2026 · filed 17 February 2026
- exercised options over 1,401 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- had shares withheld for tax on 756 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- exercised options over 1,359 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- had shares withheld for tax on 734 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- was granted 19,935 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- had shares withheld for tax on 10,755 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- exercised options over 1,600 shares of Neurocrine Biosciences (a derivative holding)SEC Form 417 February 2026Restricted Stock Unit · traded 12 February 2026 · filed 17 February 2026
- exercised options over 801 shares of Neurocrine BiosciencesSEC Form 43 February 2026Common Stock · traded 31 January 2026 · filed 3 February 2026
- had shares withheld for tax on 475 shares of Neurocrine BiosciencesSEC Form 43 February 2026Common Stock · traded 31 January 2026 · filed 3 February 2026
- exercised options over 801 shares of Neurocrine Biosciences (a derivative holding)SEC Form 43 February 2026Restriced Stock Unit · traded 31 January 2026 · filed 3 February 2026
- exercised options over 801 shares of Neurocrine Biosciences (a derivative holding)SEC Form 43 February 2026Restriced Stock Unit · traded 31 January 2026 · filed 3 February 2026
- exercised options over 801 shares of Neurocrine BiosciencesSEC Form 43 February 2026Common Stock · traded 31 January 2026 · filed 3 February 2026
- had shares withheld for tax on 475 shares of Neurocrine BiosciencesSEC Form 43 February 2026Common Stock · traded 31 January 2026 · filed 3 February 2026
- exercised options over 457 shares of Neurocrine Biosciences (a derivative holding)SEC Form 411 July 2025Non-Qualified Stock Option · traded 10 July 2025 · filed 11 July 2025
- exercised options over 457 shares of Neurocrine BiosciencesSEC Form 411 July 2025Common Stock · traded 10 July 2025 · filed 11 July 2025
- ▼ sold on the open market 457 shares of Neurocrine BiosciencesSEC Form 411 July 2025Common Stock · traded 10 July 2025 · filed 11 July 2025
- was granted 34,153 shares of Neurocrine Biosciences (a derivative holding)SEC Form 414 February 2025Stock Option · traded 12 February 2025 · filed 14 February 2025
- was granted 6,401 shares of Neurocrine Biosciences (a derivative holding)SEC Form 414 February 2025Restricted Stock Unit · traded 12 February 2025 · filed 14 February 2025
- exercised options over 1,358 shares of Neurocrine Biosciences (a derivative holding)SEC Form 414 February 2025Restricted Stock Unit · traded 13 February 2025 · filed 14 February 2025
- exercised options over 1,401 shares of Neurocrine Biosciences (a derivative holding)SEC Form 414 February 2025Restricted Stock Unit · traded 13 February 2025 · filed 14 February 2025
- exercised options over 1,358 shares of Neurocrine BiosciencesSEC Form 414 February 2025Common Stock · traded 13 February 2025 · filed 14 February 2025
- ▼ sold on the open market 716 shares of Neurocrine BiosciencesSEC Form 414 February 2025Common Stock · traded 13 February 2025 · filed 14 February 2025
- exercised options over 1,401 shares of Neurocrine BiosciencesSEC Form 414 February 2025Common Stock · traded 13 February 2025 · filed 14 February 2025
- ▼ sold on the open market 755 shares of Neurocrine BiosciencesSEC Form 414 February 2025Common Stock · traded 13 February 2025 · filed 14 February 2025
- exercised options over 801 shares of Neurocrine Biosciences (a derivative holding)SEC Form 44 February 2025Restriced Stock Unit · traded 31 January 2025 · filed 4 February 2025
- exercised options over 1,179 shares of Neurocrine Biosciences (a derivative holding)SEC Form 44 February 2025Restricted Stock Unit · traded 3 February 2025 · filed 4 February 2025
- exercised options over 801 shares of Neurocrine BiosciencesSEC Form 44 February 2025Common Stock · traded 31 January 2025 · filed 4 February 2025
- ▼ sold on the open market 422 shares of Neurocrine BiosciencesSEC Form 44 February 2025Common Stock · traded 31 January 2025 · filed 4 February 2025
- exercised options over 1,179 shares of Neurocrine BiosciencesSEC Form 44 February 2025Common Stock · traded 3 February 2025 · filed 4 February 2025
- ▼ sold on the open market 623 shares of Neurocrine BiosciencesSEC Form 44 February 2025Common Stock · traded 3 February 2025 · filed 4 February 2025
- exercised options over 272 shares of Neurocrine Biosciences (a derivative holding)SEC Form 43 January 2025Non-Qualified Stock Option · traded 31 December 2024 · filed 3 January 2025
- exercised options over 272 shares of Neurocrine BiosciencesSEC Form 43 January 2025Common Stock · traded 31 December 2024 · filed 3 January 2025
- ▼ sold on the open market 272 shares of Neurocrine BiosciencesSEC Form 43 January 2025Common Stock · traded 31 December 2024 · filed 3 January 2025
- exercised options over 1,091 shares of Neurocrine Biosciences (a derivative holding)SEC Form 419 December 2024Non-Qualified Stock Option · traded 17 December 2024 · filed 19 December 2024
- exercised options over 1,091 shares of Neurocrine BiosciencesSEC Form 419 December 2024Common Stock · traded 17 December 2024 · filed 19 December 2024
- ▼ sold on the open market 1,091 shares of Neurocrine BiosciencesSEC Form 419 December 2024Common Stock · traded 17 December 2024 · filed 19 December 2024
- exercised options over 3,043 shares of Neurocrine Biosciences (a derivative holding)SEC Form 415 August 2024Non-Qualified Stock Option · traded 13 August 2024 · filed 15 August 2024
- exercised options over 3,043 shares of Neurocrine BiosciencesSEC Form 415 August 2024Common Stock · traded 13 August 2024 · filed 15 August 2024
- ▼ sold on the open market 3,043 shares of Neurocrine BiosciencesSEC Form 415 August 2024Common Stock · traded 13 August 2024 · filed 15 August 2024
- ▼ sold on the open market 4,100 shares of Neurocrine BiosciencesSEC Form 415 August 2024Common Stock · traded 13 August 2024 · filed 15 August 2024
- exercised options over 273 shares of Neurocrine Biosciences (a derivative holding)SEC Form 48 August 2024Non-Qualified Stock Option · traded 6 August 2024 · filed 8 August 2024
- exercised options over 273 shares of Neurocrine BiosciencesSEC Form 48 August 2024Common Stock · traded 6 August 2024 · filed 8 August 2024
- ▼ sold on the open market 273 shares of Neurocrine BiosciencesSEC Form 48 August 2024Common Stock · traded 6 August 2024 · filed 8 August 2024
- exercised options over 400 shares of Neurocrine Biosciences (a derivative holding)SEC Form 418 July 2024Non-Qualified Stock Option · traded 16 July 2024 · filed 18 July 2024
- exercised options over 1,557 shares of Neurocrine Biosciences (a derivative holding)SEC Form 418 July 2024Non-Qualified Stock Option · traded 16 July 2024 · filed 18 July 2024
- exercised options over 400 shares of Neurocrine BiosciencesSEC Form 418 July 2024Common Stock · traded 16 July 2024 · filed 18 July 2024
- ▼ sold on the open market 400 shares of Neurocrine BiosciencesSEC Form 418 July 2024Common Stock · traded 16 July 2024 · filed 18 July 2024
- exercised options over 1,557 shares of Neurocrine BiosciencesSEC Form 418 July 2024Common Stock · traded 16 July 2024 · filed 18 July 2024
- ▼ sold on the open market 1,557 shares of Neurocrine BiosciencesSEC Form 418 July 2024Common Stock · traded 16 July 2024 · filed 18 July 2024
- ▼ sold on the open market 900 shares of Neurocrine BiosciencesSEC Form 418 July 2024Common Stock · traded 16 July 2024 · filed 18 July 2024
- exercised options over 272 shares of Neurocrine Biosciences (a derivative holding)SEC Form 42 July 2024Non-Qualified Stock Option · traded 1 July 2024 · filed 2 July 2024
- exercised options over 272 shares of Neurocrine BiosciencesSEC Form 42 July 2024Common Stock · traded 1 July 2024 · filed 2 July 2024
- ▼ sold on the open market 272 shares of Neurocrine BiosciencesSEC Form 42 July 2024Common Stock · traded 1 July 2024 · filed 2 July 2024
- exercised options over 273 shares of Neurocrine Biosciences (a derivative holding)SEC Form 44 June 2024Non-Qualified Stock Option · traded 31 May 2024 · filed 4 June 2024
- exercised options over 273 shares of Neurocrine BiosciencesSEC Form 44 June 2024Common Stock · traded 31 May 2024 · filed 4 June 2024
- ▼ sold on the open market 273 shares of Neurocrine BiosciencesSEC Form 44 June 2024Common Stock · traded 31 May 2024 · filed 4 June 2024
- exercised options over 273 shares of Neurocrine Biosciences (a derivative holding)SEC Form 48 May 2024Non-Qualified Stock Option · traded 6 May 2024 · filed 8 May 2024
- exercised options over 273 shares of Neurocrine BiosciencesSEC Form 48 May 2024Common Stock · traded 6 May 2024 · filed 8 May 2024
- ▼ sold on the open market 273 shares of Neurocrine BiosciencesSEC Form 48 May 2024Common Stock · traded 6 May 2024 · filed 8 May 2024
- exercised options over 272 shares of Neurocrine Biosciences (a derivative holding)SEC Form 43 April 2024Non-Qualified Stock Option · traded 1 April 2024 · filed 3 April 2024
- exercised options over 272 shares of Neurocrine BiosciencesSEC Form 43 April 2024Common Stock · traded 1 April 2024 · filed 3 April 2024
- ▼ sold on the open market 272 shares of Neurocrine BiosciencesSEC Form 43 April 2024Common Stock · traded 1 April 2024 · filed 3 April 2024
- exercised options over 5,000 shares of Neurocrine Biosciences (a derivative holding)SEC Form 425 March 2024Non-Qualified Stock Option · traded 21 March 2024 · filed 25 March 2024
- exercised options over 5,000 shares of Neurocrine BiosciencesSEC Form 425 March 2024Common Stock · traded 21 March 2024 · filed 25 March 2024
- ▼ sold on the open market 5,000 shares of Neurocrine BiosciencesSEC Form 425 March 2024Common Stock · traded 21 March 2024 · filed 25 March 2024
- exercised options over 3,000 shares of Neurocrine Biosciences (a derivative holding)SEC Form 415 March 2024Non-Qualified Stock Option · traded 13 March 2024 · filed 15 March 2024
- exercised options over 3,000 shares of Neurocrine BiosciencesSEC Form 415 March 2024Common Stock · traded 13 March 2024 · filed 15 March 2024
- ▼ sold on the open market 3,000 shares of Neurocrine BiosciencesSEC Form 415 March 2024Common Stock · traded 13 March 2024 · filed 15 March 2024
- exercised options over 1,800 shares of Neurocrine Biosciences (a derivative holding)SEC Form 412 March 2024Non-Qualified Stock Option · traded 8 March 2024 · filed 12 March 2024
- exercised options over 200 shares of Neurocrine Biosciences (a derivative holding)SEC Form 412 March 2024Non-Qualified Stock Option · traded 11 March 2024 · filed 12 March 2024
- exercised options over 1,800 shares of Neurocrine BiosciencesSEC Form 412 March 2024Common Stock · traded 8 March 2024 · filed 12 March 2024
- ▼ sold on the open market 1,800 shares of Neurocrine BiosciencesSEC Form 412 March 2024Common Stock · traded 8 March 2024 · filed 12 March 2024
- exercised options over 200 shares of Neurocrine BiosciencesSEC Form 412 March 2024Common Stock · traded 11 March 2024 · filed 12 March 2024
- ▼ sold on the open market 200 shares of Neurocrine BiosciencesSEC Form 412 March 2024Common Stock · traded 11 March 2024 · filed 12 March 2024
- exercised options over 2,500 shares of Neurocrine Biosciences (a derivative holding)SEC Form 429 February 2024Non-Qualified Stock Option · traded 28 February 2024 · filed 29 February 2024
- exercised options over 2,500 shares of Neurocrine Biosciences (a derivative holding)SEC Form 429 February 2024Non-Qualified Stock Option · traded 28 February 2024 · filed 29 February 2024
- exercised options over 1,544 shares of Neurocrine Biosciences (a derivative holding)SEC Form 429 February 2024Non-Qualified Stock Option · traded 28 February 2024 · filed 29 February 2024
- exercised options over 273 shares of Neurocrine Biosciences (a derivative holding)SEC Form 429 February 2024Non-Qualified Stock Option · traded 29 February 2024 · filed 29 February 2024
- exercised options over 2,500 shares of Neurocrine BiosciencesSEC Form 429 February 2024Common Stock · traded 28 February 2024 · filed 29 February 2024
- ▼ sold on the open market 2,500 shares of Neurocrine BiosciencesSEC Form 429 February 2024Common Stock · traded 28 February 2024 · filed 29 February 2024
- exercised options over 2,500 shares of Neurocrine BiosciencesSEC Form 429 February 2024Common Stock · traded 28 February 2024 · filed 29 February 2024
- ▼ sold on the open market 2,500 shares of Neurocrine BiosciencesSEC Form 429 February 2024Common Stock · traded 28 February 2024 · filed 29 February 2024
- exercised options over 1,544 shares of Neurocrine BiosciencesSEC Form 429 February 2024Common Stock · traded 28 February 2024 · filed 29 February 2024
- ▼ sold on the open market 1,544 shares of Neurocrine BiosciencesSEC Form 429 February 2024Common Stock · traded 28 February 2024 · filed 29 February 2024
- exercised options over 273 shares of Neurocrine BiosciencesSEC Form 429 February 2024Common Stock · traded 29 February 2024 · filed 29 February 2024
- ▼ sold on the open market 273 shares of Neurocrine BiosciencesSEC Form 429 February 2024Common Stock · traded 29 February 2024 · filed 29 February 2024
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.